Bayer Lists Stock on New York Exchange Amid Marked Increase in Reported Baycol Deaths, Management Shake-Up

ic Aendic week before Bayer AG was to take its seat on the New York Stock Exchange, the company announced that it now believes that twice as many people as previously reported have died after ingesting Baycol.

photo-1 In a document released to the Securities and Exchange Commission on Jan. 15, Bayer noted that more than 100 people who were diagnosed with rhabdomyolysis while taking Baycol are now deceased, while so far nearly 1,600 have been diagnosed with a non-fatal form of the condition.

In its most severe form, rhabdomyolysis can cause kidney failure. Until Bayer's statement, it …